However, resistant cells can end up repopulating. T (CAR-T) cell therapy can also be used, this involves the manipulation/reprogramming of immune cells of the patients in order to attack tumor T cells. Multiple trials have been underway leading to new advancements and improvements in these trials which will lead to an increase in success of future trials. The article also discusses the CRISPR system that allows inactivation of exogenous sequences and allele substitution which promotes gene editing. The authors conclude that genetic therapy in somatic cells have been largely approved by the scientific community specifically in cases of disorders, but germline gene therapy is where the ethical issues arise. On one side there is the Japanese Ethics Committee that believes the experiments conducted were correct since they had been approved by the ethics committee and had consent from egg donors. While on the other side American research groups did not support these experiments and needed to await improvements of techniques. There needs to be a more solid understanding of techniques before they can be widely used.
Recent comments